Literature DB >> 15111021

Subsets of acetylcholine-stimulated 86Rb+ efflux and [125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment.

Michael J Marks1, Peter P Rowell, Jian-Zhe Cao, Sharon R Grady, Sarah E McCallum, Allan C Collins.   

Abstract

Nicotinic cholinergic receptor (nAChR) sites that bind nicotine with high affinity (likely alpha4beta2-nAChR) increase following chronic nicotine treatment. Effects of chronic treatment on other nAChR binding sites and functional responses of nAChRs are less well studied. Therefore, C57BL/6 mice were intravenously infused for 10 days with saline or nicotine (five doses, 0.25-4.0 mg/kg/h) and nAChR function and three different nicotinic binding sites in 12 brain regions were assessed. Plasma nicotine and cotinine increased linearly with dose. 86Rb+ efflux with higher sensitivity to acetylcholine tended to decrease with increasing dose, whereas efflux with lower sensitivity to acetylcholine tended to increase. As anticipated, likely alpha4beta2-nAChR [125I]-epibatidine binding sites increased with treatment (estimated dosage for one-half maximal increase was 0.44 mg/kg/h, plasma nicotine approximately 20 ng/ml). 86Rb+ efflux with higher sensitivity to acetylcholine and cytisine-sensitive [125I]-epibatidine binding are predominantly alpha4beta2-nAChR. A high correlation between these parameters was observed across brain regions and slopes of these regression lines decreased with treatment dose, suggesting a decrease in function per unit receptor. Likely alpha3beta4-nAChR binding sites were unaffected even at the highest dose (4.0 mg/kg/h, approximately 210 ng/ml). A third set of diverse nAChR binding sites increased in some brain regions, but only after high-dose treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111021     DOI: 10.1016/j.neuropharm.2004.02.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  45 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

2.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

3.  Spectral confocal imaging of fluorescently tagged nicotinic receptors in knock-in mice with chronic nicotine administration.

Authors:  Anthony Renda; Raad Nashmi
Journal:  J Vis Exp       Date:  2012-02-10       Impact factor: 1.355

4.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

Review 5.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

6.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Authors:  Raad Nashmi; Cheng Xiao; Purnima Deshpande; Sheri McKinney; Sharon R Grady; Paul Whiteaker; Qi Huang; Tristan McClure-Begley; Jon M Lindstrom; Cesar Labarca; Allan C Collins; Michael J Marks; Henry A Lester
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 7.  Nicotine and hippocampus-dependent learning: implications for addiction.

Authors:  Thomas J Gould
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 8.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

9.  Chronic nicotine alters nicotinic receptor-induced presynaptic Ca2+ responses in isolated nerve terminals.

Authors:  John J Dougherty; Jianlin Wu; Tejal K Mehta; Brett Brown; Robert A Nichols
Journal:  Neurochem Res       Date:  2007-12-20       Impact factor: 3.996

Review 10.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.